Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 1780Neoplasms 1500Carcinoma, Non-Small-Cell Lung 1045Prostatic Neoplasms 958Colorectal Neoplasms 882Lung Neoplasms 803Pancreatic Neoplasms 573Carcinoma, Hepatocellular 543Leukemia, Myeloid, Acute 541Stomach Neoplasms 513Ovarian Neoplasms 508Neoplasm Metastasis 499Multiple Myeloma 494Recurrence 412Melanoma 387Squamous Cell Carcinoma of Head and Neck 370Brain Neoplasms 362Uterine Cervical Neoplasms 361Head and Neck Neoplasms 356Esophageal Neoplasms 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 306Endometrial Neoplasms 305Triple Negative Breast Neoplasms 299Glioblastoma 299Rectal Neoplasms 282Sarcoma 266Urinary Bladder Neoplasms 264Hematologic Neoplasms 264Colonic Neoplasms 255

Interventions

Epirubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hormone Receptor Positive HER-2 Negative Breast Cancer × Clear all
NCT05878314 2026-02-10

Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

University Hospital Tuebingen

Recruiting
504 enrolled
Breast

Hormone Receptor Positive HER-2 Negative Breast Cancer

NCT05901428 2023-06-15

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Fudan University

Phase 3 Recruiting
1,736 enrolled
Breast

Hormone Receptor Positive HER-2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡